Ehave Inc - EHVVF STOCK NEWS

Ehave, Inc. (OTC Pink: EHVVF) announced a partnership with Heally to enhance its KetaDASH platform. This collaboration will provide licensed psychotherapists and registered nurses for patients seeking alternative treatments like ketamine therapy. The KetaDASH service offers in-home psychedelic therapy sessions, connecting patients with professionals via Heally's telehealth portal. This move is seen as a response to rising mental health issues exacerbated by the COVID-19 pandemic, aiming to improve access to care and patient outcomes in the mental health sector.

Ehave, Inc. (OTC Pink: EHVVF) has licensed advanced AI technology from Vastmindz to enhance its MetaHealthU offerings. Set to monetize this technology in 2022, Ehave aims to integrate features in its Ehave Dashboard to monitor vital statistics such as Heart Rate and Oxygen Saturation through facial light absorption analysis. Vastmindz's CEO recently showcased their innovation on the Unicorn Hunters platform, a show with over 14.5 million viewers, receiving positive remarks from tech experts like Steve Wozniak. This partnership is positioned to broaden healthcare accessibility globally.

Ehave, Inc. (EHVVF) has launched KetaDASH, a managed service offering in-home ketamine therapy for patients with treatment-resistant mental health issues. The service starts in the San Francisco Bay Area and Greater Sacramento Area, with plans to expand. KetaDASH focuses on safety and patient comfort, featuring a team of qualified professionals providing treatments after an initial telemedicine consultation. This initiative aims to broaden access to ketamine therapy, which has shown promise in treating conditions like depression and PTSD, thereby enhancing patient outcomes.

Ehave, Inc. (OTC Pink: EHVVF) announced the acquisition of Rejuv IV, enhancing its KetaDASH brand. This mobile IV therapy provider, active in the San Francisco Bay Area, offers services such as Ketamine treatments and IV Vitamin Therapy. CEO Ben Kaplan emphasized the company's commitment to mental health, highlighting KetaDASH’s role in providing lifesaving treatments for psychiatric disorders like depression and PTSD. The service combines at-home administration with telehealth supervision, expanding Ehave's reach in mental health therapeutics.

Ehave, Inc. (EHVVF) shares insights in a letter to shareholders from CEO Ben Kaplan, highlighting advancements in digital therapeutics for mental health using psychedelics. The company emphasizes mental health issues affecting millions in the U.S. and aims to enhance treatments. Key developments from 2021 include a strengthened balance sheet and successful product development. With plans to monetize technology through licensing, Ehave anticipates significant growth. Additionally, Ehave will distribute 30% of PSLY.COM holdings to shareholders and targets launching the KetaDASH home delivery service soon.

Ehave has signed a Letter of Intent (LOI) with Ei.Ventures to explore a merger forming PSLY.COM, an estimated $360 million transaction. As part of this process, Ehave plans to spin out 30% of its Mycotopia Therapies shares to existing shareholders. Ehave currently holds approximately 9.8 million shares of Mycotopia, which focuses on psilocybin-based therapeutics. The merged companies aim to list on NASDAQ after completing pre-clinical trials for their flagship product, Psilly. This move is seen as a strategic shift towards enhancing shareholder value and market presence.

Ehave, Inc. (EHVVF) announced its KetaDASH platform will sponsor the 2021 Psychedelic Investor Guide. KetaDASH is an IV-based home delivery service for ketamine therapy aimed at enhancing patient care. CEO Ben Kaplan highlighted the platform's HIPAA compliance and early market entry. The Investor Guide features 46 prominent companies in the psychedelic sector, providing essential investment data, including stock charts and financial information. This comprehensive guide will be updated monthly and aims to simplify research for investors in the rapidly developing psychedelic investment landscape.

Ehave, based in Miami, has initiated a ketamine clinical trial aimed at exploring the potential of ketamine to promote neuroplasticity and address mental health issues. The company has engaged KGK Science Inc. to develop the necessary protocol and Informed Consent Form for its Institutional Review Board application. The trial will involve four ketamine infusions for each patient, with the goal of obtaining objective data to support the treatment's effectiveness for depression and related conditions. Ehave also plans to expand its KetaDASH platform to enhance mental health care.

Ehave, Inc. (OTC Pink: EHVVF) announced on September 30, 2021, that the Psychedelic Stock Review has initiated coverage of the company. Ehave is set to launch a range of digital tools aimed at enhancing the effectiveness of Psychedelic treatments. The company previously sold its Clinical Software Platform for $3.2 million and is transitioning to provide patient reporting services in the Psychedelic sector. Key upcoming products include KetaDash, MegaTeam, and the Ehave Health Records Dashboard, all designed to improve patient monitoring and data collection in the growing market for Psychedelic therapies.